Overview

Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Primary objectives: - To determine the time to progression in subjects with breast cancer metastatic to bone only treated with 153Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT). Secondary objectives: - To determine the overall survival at one year. - To determine the efficacy of 153Sm-EDTMP at 6 months. - To assess pain in subjects treated with 153Sm-EDTMP. - To determine the safety of 153Sm-EDTMP.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Cytogen Corporation
Treatments:
Samarium ethylenediaminetetramethylenephosphonate
Samarium Sm-153 lexidronam